Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 745,843 | 876,750 | 622,909 | 1,321,149 | 1,559,642 | 5,126,293 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | 0 | |||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | 0 | |||||
| 4 | Total. Add lines 1 through 3 | 745,843 | 876,750 | 622,909 | 1,321,149 | 1,559,642 | 5,126,293 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 296,703 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 4,829,590 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 745,843 | 876,750 | 622,909 | 1,321,149 | 1,559,642 | 5,126,293 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 122 | 147 | 90 | 9,463 | 28,749 | 38,571 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 0 | |||||
| 11 | Total support. Add lines 7 through 10 | 5,164,864 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2024 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2024 |
(iii) Distributable Amount for 2024 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2024 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2024 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2024: | ||||
| a From 2019....... | ||||
| b From 2020....... | ||||
| c From 2021....... | ||||
| d From 2022....... | ||||
| e From 2023....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2024 distributable amount | ||||
|
i
Carryover from 2019 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2024 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2024 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2024, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2024. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2025. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2020..... | ||||
| b Excess from 2021..... | ||||
| c Excess from 2022..... | ||||
| d Excess from 2023..... | ||||
| e Excess from 2024..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|
| Software ID: | 24020486 |
| Software Version: | 2024v5.2 |
| Return Reference | Explanation |
|---|---|
| Form 990, Part VI, Section B, Line 11b | An electronic copy of Form 990 is provided to the Board of Directors for review before filing. |
| Form 990, Part VI, Section B, Line 12c | The Conflict of Interest Committee is a standing committee and shall consist of no fewer than three directors. The Conflict of Interest Committee is responsible for identifying, investigating and advising the Board with respect to existing and/or potential transactions that may benefit the private interest of a director or Officer of the Corporation in accordance with the Conflict of Interest Policy of the Corporation annexed to the by-laws as Annex A, interpreting the Conflicts of Interest Policy, reporting to the Board on its actions no less than annually, and conducting periodic reviews of the Corporation's activities to identify potential and/or actual Interested Party transactions. Subject to the provisions of this Section 5.4 and Annex A, the Conflict of Interest Committee shall have such additional purpose, membership, general and specific functions and responsibilities as may be provided for in any committee charter of the Conflict of Interest Committee approved by the entire Board. |
| Form 990, Part VI, Section B, Line 15b | ALCMI's CEO is not compensated. Regarding the compensation paid to the Senior Director of Clinical Operations, the CEO conducts reviews, checks Non Profit compensation reports from CA NonProfits. The board also reviews. This process occurred during 2020. |
| Form 990, Part VI, Section C, Line 19 | The Organization shall make available its governing documents, conflict of interest policy and financial statements upon request. |
| Form 990, Part III, 4a- Program Expenses | (Cont'd. from page 2) ALCMI's researchers are pooling their knowledge, specimens and data in order to improve the understanding of the molecular bases of lung cancer and to accelerate the development and delivery of much more effective, targeted drugs and treatments tailored to individual patient types. ALCMI has developed, conducted, and published a number of innovative research studies that would otherwise not have existed: 1) CASTLE: a prospective, longitudinal, multi-center study with serial biobanked advanced stage lung cancer specimens that are also annotated with clinical/molecular data. 2) INHERIT EGFR T790M: a prospective study on germline biology in high-risk families; to identify specific inherited genetic markers indicating risk of developing lung cancer. 3) Genomics of Young Lung Cancer (GoYLC): a prospectively performed comprehensive genomic profiling to determine whether young lung cancers harbor a distinctive spectrum of genetic mutations, and therefore unique treatment strategies (peer-reviewed paper published in 2021, Journal of Thoracic Oncology). Other studies in progress are 4) Epidemiology of Young Lung Cancer (EoYLC): a remote decentralized survey study designed to identify lifestyle, environmental, and family/genetic risk factors associated with the development of lung cancer under the age of 50, and any possible connection to specific cancer-driving mutations. Data from this trial has now been presented at several national and international cancer conferences. The sponsor-funder of this trial has closed enrollment, and results from this trial have recently been submitted for feature at the 2026 American Academy of Cancer Research (AACR) conference. Plans are also to submit results to the 2026 World Conference Lung Cancer (Sept, Seoul). 5) SPACEWALK: a study to investigate the relationship between specific ALK resistance mutations and specific next generation ALK TKI therapies received before progression. The results of this trial were published in the Journal of Thoracic Oncology. 6) BEACON-LUNG: a multicenter study collecting serum, plasma, tissue, and CT images from patients receiving pembrolizumab or pembrolizumab plus carboplatin-based chemotherapy to help identify patients who may benefit from a more aggressive triplet treatment regimen. This test utilizes mass spectrometry with machine learning and was developed by Biodesix, Inc. to classify patients as responders or non-responders, which could help identify patients who may benefit from a triplet treatment regimen. This trial was closed prematurely by the sponsor-funder. 7) ENIGMA+: a remote decentralized study collecting tissue and sputum specimens and clinical outcome data across patients diagnosed with ALK+ mutation NSCLC. ALCMI recently achieved the enrollment goal for this study. 8) SPARK: a remote decentralized study collecting blood specimens and clinical outcome data across patients diagnosed with KRAS mutation NSCLC. The sponsor-funder of this trial has closed enrollment, and results from this trial have recently been submitted for feature at the 2026 American Academy of Cancer Research (AACR) conference. 9) TURN-AROUND-TIME: a regional, community hospital-based project aimed at establishing de novo Next Generation Sequencing (NGS) testing in facilities that heretofore rely on external "send-out" lab testing, and a research trial to test the hypothesis that putting NGS data into the hands of treating oncologists sooner can improve downstream patient treatment outcomes. 10) INHERIT 2.0: a new prospective study on germline biology in high-risk families using a more advanced panel of biomarkers; to identify specific inherited genetic markers indicating risk of developing lung cancer. 11) SUCCEED: a pilot feasibility trial to determine the viability and barriers of enrolling patients diagnosed with Small Cell Lung cancer (SCLC) into a remote decentralized format study. |
| Software ID: | 24020486 |
| Software Version: | 2024v5.2 |